Abstract 499P
Background
EGFR mutations occur in about half of the advanced non-squamous NSCLC patients in East Asia. Majority of the common activating mutations like L858R, exon 19 deletions (del) and T790M are detected by hot spot test methods in Hong Kong. However, hot spot test may not detect other uncommon EGFR alterations like point mutations, exon 20 insertions and amplifications, in which the best treatment remains undefined. Using a comprehensive liquid biopsy we investigated the prevalence of these uncommon EGFR alterations in ctDNA from NSCLC patients.
Methods
All Guardant360 (Guardant Health, Redwood City, CA) requests ordered in Hong Kong between Jan 2016 and June 2019 were reviewed. This is a next-generation ctDNA sequencing (NGS) panel of 74 cancer-related genes, including complete exon sequencing of EGFR. We identified cases with a diagnosis of “lung cancer” and excluded pure squamous, small cell, neuroendocrine and sarcomatoid histology. Uncommon EGFR alterations, defined as amplification or mutations other than L858R, exon 19 del, or T790M were identified. Synonymous mutations and variants of unknown significance were excluded. Demographics and impact of results to subsequent management will be analyzed and presented later.
Results
A total of 282 non-squamous NSCLC patients were tested. Samples came from 146 women and 136 men, with a median age 60. ctDNA was identified in 241 samples (85.5% detection rate). EGFR alterations were identified in 95 samples (39.4%), including L858R (48), exon 19 del (27), and T790M (24). Uncommon alterations were found in 47 of 95 EGFR cases (49.5%); 18 of these had no co-existing common EGFR or other driver mutation. These included amplifications (8); exon 20 insertions (8); L861Q (2); and other point mutations (4); 4 cases had an uncommon mutation with amplification.
Conclusions
Using a comprehensive ctDNA NGS panel, 47 out of 241 (19.5%) non-squamous NSCLC patients with uncommon EGFR alterations were detected. Novel NGS methods can help identify this group of patients with unmet needs for a gene-directed therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Guardant Health AMEA.
Funding
Has not received any funding.
Disclosure
O.S.H. Chan: Full / Part-time employment: Hong Kong Integrated Oncology Centre; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Merck Sharp & Dohme. G.Y. Cheung: Full / Part-time employment: Sanomics Limited. M.M.L. Lee: Full / Part-time employment: Guardant Health AMEA. S. Olsen: Full / Part-time employment: Guardant Health AMEA; Shareholder / Stockholder / Stock options: Guardant Health Inc; Shareholder / Stockholder / Stock options: AstraZeneca.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract